0001209191-19-044881.txt : 20190806 0001209191-19-044881.hdr.sgml : 20190806 20190806181432 ACCESSION NUMBER: 0001209191-19-044881 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190802 FILED AS OF DATE: 20190806 DATE AS OF CHANGE: 20190806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davidson Matt CENTRAL INDEX KEY: 0001741937 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 191003409 MAIL ADDRESS: STREET 1: C/O VERRICA PHARMACEUTICALS INC. STREET 2: 10 NORTH HIGH STREET, SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-02 0 0001660334 Verrica Pharmaceuticals Inc. VRCA 0001741937 Davidson Matt C/O VERRICA PHARMACEUTICALS INC. 10 NORTH HIGH STREET, SUITE 200 WEST CHESTER PA 19380 0 0 1 0 Common Stock 2019-08-02 4 S 0 1969 10.78 D 2588775 D Common Stock 2019-08-05 4 S 0 1679 10.65 D 2587096 D Common Stock 2019-08-06 4 S 0 2602 10.28 D 2584494 D These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.28 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-Fact 2019-08-06